Biotechnology · Healthcare
Chief Accounting Officer, CFO
2023-09-18–present
Chief Accounting Officer
C4 Therapeutics, Inc. (CCCC)Equibles does not estimate personal net worth.
Get an email with a short summary when C4 Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get CCCC alertsKendra R. Adams is recorded as Chief Accounting Officer at C4 Therapeutics, Inc. (CCCC) since May 15, 2026 and CFO at C4 Therapeutics, Inc. (CCCC) since September 18, 2023. The newest filing on record that lists Kendra R. Adams as CFO at C4 Therapeutics, Inc. (CCCC) is dated April 29, 2026. C4 Therapeutics, Inc. reported in an 8-K filed May 15, 2026 that Kendra R. Adams was appointed principal accounting officer, effective May 15, 2026. C4 Therapeutics, Inc. reported in an 8-K filed September 5, 2023 that Kendra R. Adams was appointed Chief Financial Officer, Treasurer and principal financial officer, effective September 18, 2023. The proxy statement of C4 Therapeutics, Inc. reports total compensation of $1,476,789 for Kendra R. Adams in fiscal 2025, including a base salary of $506,825. Disclosed compensation is on record for 3 fiscal years. Kendra R. Adams has spoken on 1 investor event across 1 company, most recently for C4 Therapeutics, Inc. on September 10, 2026. C4 Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at C4 Therapeutics, Inc. includes Andrew J. Hirsch (CEO), Andrew Phillips (CEO), Ron Cooper (Chairman and Board Member) and 7 others.
“Kendra R. Adams, the Company's Chief Financial Officer, Head of Corporate Affairs and Treasurer, has been designated as the Company's principal accounting officer, effective May 15, 2026.”
“On September 5, 2023, the Company announced the appointment of Kendra Adams as its Chief Financial Officer, Treasurer and principal financial officer, effective as of Monday September 18, 2023.”
“We are a targeted protein degrader company, and we have a portfolio of degraders that we're looking to bring to patients with unmet needs. I'll start with our lead program, which is simsidamide.”
2026-05-15–present
2023-09-18–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
Chief Accounting Officer, CFO
2023-09-18–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | C4 Therapeutics, Inc. (CCCC) | Chief Financial Officer | $506,825 | $1,476,789 |
| 2024 | C4 Therapeutics, Inc. (CCCC) | Chief Financial Officer | $485,000 | $2,197,489 |
| 2023 | C4 Therapeutics, Inc. (CCCC) | Chief Financial Officer | $404,553 | $1,210,598 |